RGEN logo

REPLIGEN CORP

RGENNASDAQ
πŸ† #750 by market capEarnings Feb 22 Β· PreUS Equity
$184.69β–² $8.90 (+5.06%)
πŸŒ™ After hours$185.73β–² 0.56%Regular close Β· extended-hours price shown
πŸ””
Track RGEN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 5.1%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$11.73B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
16.5%
Healthy
πŸ“ŠGross Margin
53.8%
Healthy
πŸ’΅FCF Margin
14.0%
Healthy
βš–οΈP/S Ratio
14.2x
Expensive
Otter Score
64
Fair
No chart data available for RGEN.

Trading Snapshot

Day Range
$173.54 – $185.88
52-Week Range
$100.99 – $198.87
Volume (shares)
1,447,759
Avg Volume (shares)
β€”
Shares Outstanding
63.5M
Next Earnings
2027-02-22

Fundamentals Snapshot

Annual Revenue
$738M
Last Q Revenue
$204M
P/E Ratio
268.5
P/S Ratio
14.2x
EPS (TTM)
$0.73
Dividend Yield
β€”
Dilution (1yr)
+0.8%
RGEN logo

REPLIGEN CORP

RGEN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$738Mβ–² +16.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
47.1%β–² +8.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$60Mβ–Ό βˆ’269.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$94Mβ–Ό βˆ’34.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
56.5Mβ–² +0.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$124Mβ–Ό βˆ’$195M YoY
StockOtter Β· stockotter.space

About REPLIGEN CORP

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Ratings

β“˜
Consensus
Buy
27 analysts
Strong Buy7
Buy16
Hold4
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

Seeking AlphaΒ·1d ago

Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript

Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript

MarketBeatΒ·1d ago

What Repligen (RGEN) Said on Its Q3 Earnings Call

Repligen NASDAQ: RGEN reported record third-quarter 2026 revenue of $209 million, surpassing its prior quarterly peak set in the second quarter of 2022, as growth in its Proteins, Chromatography and Analytics franchises

Seeking AlphaΒ·1d ago

Conestoga Small Cap Composite Q3 2026 Portfolio Activity

The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, trailing the -9.39% return for the Russell 2000 Growth Index. Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, De

Zacks Investment ResearchΒ·1d ago

Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates

Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.46 per share a year ago.

GlobeNewsWireΒ·1d ago

Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic Closed BioLife acquisition, which fast-tracks Repligen's leadership and offering in high-growth cell therapy market Ra

Seeking AlphaΒ·2d ago

Baron Health Care Fund Q3 2026 Top Contributors And Detractors

TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised guid